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Abstract: Uveal melanoma (UM) has well-characterised somatic copy number alterations (SCNA) 20 
in chromosomes 1, 3, 6 and 8, in addition to mutations in GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, 21 
SF3B1 and EIF1AX, most being linked to metastatic-risk. To gain further insight into the molecular 22 
landscape of UM, we designed a targeted next-generation sequencing (NGS) panel to detect SCNA 23 
and mutations in routine clinical UM-samples.  We compared hybrid-capture and amplicon-based 24 
target enrichment methods and tested a larger cohort of primary UM-samples on the best 25 
performing panel. UM clinical samples processed either as fresh-frozen, formalin-fixed paraffin 26 
embedded (FFPE), small intraocular biopsies or following irradiation were successfully profiled 27 
using NGS, with hybrid capture outperforming the PCR-based enrichment methodology. We 28 
identified monosomy 3 (M3)-UM that were wild-type for BAP1 but harboured SF3B1 mutations, 29 
novel frameshift deletions in SF3B1 and EIF1AX, as well as a PLCB4 mutation outside of the hotspot 30 
on exon 20 coinciding with a GNAQ mutation in some UM. We observed samples that harboured 31 
mutations in both BAP1 and SF3B1, and SF3B1 and EIF1AX, respectively. Novel mutations were 32 
also identified in TTC28, KTN1, CSMD1 and TP53BP1. NGS can simultaneously assess SCNA and 33 
mutation data in UM, in a reliable and reproducible way, irrespective of sample type or previous 34 
processing. BAP1 and SF3B1 mutations, in addition to 8q copy number, are of added importance 35 
when determining UM patient outcome. 36 
Keywords: Next-generation sequencing; uveal melanoma; prognostication; mutation; clinical 37 
samples; chromosome; copy number 38 
 39 
1. Introduction: 40 
Uveal melanoma (UM), the most common primary intraocular malignancy in adults, has an 41 
incidence of 3-8 individuals per million per year in Caucasians [1,2]. Despite successful treatment of 42 
the primary tumor with surgery and/or radiotherapy, metastatic death occurs in ~50% of patients 43 
[3,4]. Stratifying UM-patients based on their metastatic-risk is essential for efficient, personalised 44 
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care. In Liverpool, UM-patients are currently stratified into metastatic-risk groups – i.e. low (LR) or 45 
high (HR) risk - using a combination of clinical, histopathological and genetic factors [5,6]. Patients 46 
with HR-UM undergo regular liver imaging using magnetic resonance imaging (MRI) to enable early 47 
detection of metastases, and thereby enhance opportunities for liver resection and enrolment into 48 
clinical trials [5]. Liver resection has been shown to prolong the median survival of UM-patients by 49 
19 months compared with patients treated palliatively [7]. Conversely, patients with LR-UM can be 50 
reassured, avoiding long-term surveillance, with proven benefits both to them and to health service 51 
providers [3].  52 
Distinct somatic copy number alterations (SCNA) occur in UM, the most common being 53 
monosomy 3 (M3) [8]. This corresponds with a significantly worse prognosis, especially when 54 
accompanied by polysomy chromosome (chr) 8q [9,10]. Increasing copies of chr 8q significantly 55 
correlate with reduced survival, in a dose‐dependent fashion [11]. SCNA in chr 1p, 6p and 6q have 56 
also been linked with survival outcomes [11-14].  57 
In addition to these well-characterised SCNA, UM has two sets of driver mutations: one which 58 
initiates tumorigenesis in the form of mutually exclusive gain-of-function mutations 59 
in GNAQ, GNA11, CYSLTR2, or PLCB4, major players in the Gq signalling pathway [15-18]; and the 60 
other consists of mutations in BAP1 [19], SF3B1/SRSF2 [11,20] and EIF1AX [20], which have been 61 
correlated with high-, intermediate- and low-metastatic risk groups, respectively [11]. Inactivating 62 
mutations in BAP1 are closely associated with HR-M3 UM, with recent data suggesting bi‐allelic 63 
inactivation of BAP1 is required to influence prognosis [21]. Missense mutations in splicing 64 
factor SF3B1 is often observed in disomy 3 (D3) UM and have been shown to predispose patients to 65 
late-onset metastatic disease [22]. Similarly, mutations in SRSF2, another member of the spliceosome, 66 
are observed in D3-UM, suggesting there are some functional similarities between SRSF2- 67 
and SF3B1-mutant UM [11]. Mutations in EIF1AX are mainly observed in D3-UM and are associated 68 
with LR-UM [23]. Other mutations in FBXW7 [20], DLK2, CSMD1, KTN1, TP53BP1, TTC28 [14] and 69 
MAPKAPK5 [11] have also been observed at low frequencies; however, their clinical significance 70 
remains unknown. 71 
Recent genomic studies reported that UM could be subdivided into four main groups using 72 
unsupervised hierarchical clustering according to genetic alterations (SCNA, mutations and RNA-73 
Seq), which were associated with an increasingly poor prognosis [11,14]. Based on these findings, 74 
there have been several efforts to design targeted next-generation sequencing (NGS) panels 75 
specifically for UM. In 2017, a bespoke NGS panel was designed to examine mutations in skin 76 
melanoma and UM simultaneously; however, this only examined mutations in GNAQ and GNA11, 77 
which are not associated with patient prognosis [24]. Another panel combined SCNA analysis of 78 
chromosomes 1, 3 and 8 and mutation analysis of GNAQ, GNA11, BAP1, SF3B1 and EIF1AX using 79 
the Ion Torrent (Thermofisher Scientific) sequencing platform [25]. More recently a pan-cancer 80 
sequencing panel consisting of 500 genes frequently mutated in cancer (including those frequently 81 
mutated in UM) was used to analyse 62 non-irradiated biopsies and fresh resection UM-samples [26], 82 
and also in another study, 35 matched primary UM and their metastases [27]. The studies reported 83 
the successful detection of SCNA and mutations that may enhance survival prognostication. Castle 84 
Biosciences have also developed a 7-gene NGS panel ‘DecisionDx-UMSeq’, although to our 85 
knowledge this is not compatible with fresh and formalin-fixed paraffin embedded (FFPE) or 86 
irradiated material. 87 
This study details the largest cohort of UM-patients to be analysed using a targeted NGS panel 88 
to date. We examined the ability of NGS to detect both SCNA in chr. 1, 3, 6 and 8, and mutations in 89 
GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1, SRSF2, EIF1AX, FBXW7, DLK2, CSMD1, KTN1, 90 
TP53BP1 and TTC28, in irradiated UM, as well as in FFPE tumor samples. Hybrid capture and PCR-91 
based enrichment methods for NGS were initially compared. Following this, the best technology was 92 
chosen for the evaluation of a larger UM cohort, and all genetic data were correlated with clinical and 93 
histopathological features, and with patient outcome.  94 
2. Results: 95 
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2.1. Patient and tumor demographics  96 
DNA from primary UM-samples with a median follow-up of 65 months (range 0 – 132 months) 97 
were from 117 consenting patients treated at the Liverpool Ocular Oncology Centre (LOOC), Royal 98 
Liverpool University Hospital NHS Trust. Of the UM-samples analysed 27/117 (23%) were biopsies 99 
that had residual DNA available (stored at -80°C), 14/117 (12%) specimens were FFPE and 76/117 100 
(65%) were frozen, resection samples. from which DNA could be extracted. Twenty-six cases were 101 
selected as they were taken post-irradiation with either ruthenium plaque radiotherapy (PRXT) or 102 
proton beam radiotherapy (PBR) (Figure 1). All samples had previously undergone routine genetic 103 
testing by either multiplex ligation dependent probe amplification (MLPA) or microsatellite analysis 104 
(MSA).  105 
The study consisted of 63 males and 54 females with a median age 64; range 16 – 87 years (mean 106 
age 62 years)  at the time of management of their primary UM. Primary management was 107 
enucleation in 78/117 (66%) UM-patients; local resection 12/117 (10%); endoresection 1/117 (1%); 108 
PRXT 16/117 (14%); and PBR in 10/117 (9%). Secondary treatment was necessary for 4/117 (4%) UM-109 
patients as a result of tumor recurrence (Table 1). Figure 1 describes the flow of patients through this 110 
study.  111 
The UM median largest basal diameter (LBD) was 15.0; range 4 – 22mm (mean 14.6 mm)  with 112 
a median ultrasound height (UH) 7.5; range 1 – 15.7 mm (mean  7.5 mm)  (Table 1). The AJCC stage 113 
was: 14/117 (12%) stage 1, 26/117 (22%) stage 2, 57/117 (49%) stage 3 and 20/117 (17%) stage 4. Ciliary 114 
body involvement was reported in 36/117 (31%) cases and extraocular UM extension was present in 115 
9/117 (8%) of cases. Epithelioid cells were seen in 50/117 (43%) of cases with the remaining 67/117 116 
(57%) having a spindle cell morphology. Full histological assessment was only undertaken in 117 
resection specimens (enucleation or local resection samples; n = 90), which had a mean mitotic count 118 
of 7/40hpf (median 5/40hpf; range 1 – 72/hpf). Closed Periodic Acid Schiff (PAS) + connective tissue 119 
loops were identified in 47/90 (52%) cases, and focal necrosis was observed in 21/89 (24%) cases. At 120 
study closure (23/09/2019), 62/117 (53%) patients were alive without evidence of metastasis, 40/117 121 
(34%) patients had died from metastatic disease, 11/117 (10%) patients died from other causes and 122 
4/117 (3%) patients were lost to follow-up. 123 
Table 1. Patient and tumor demographics of n=117 UM patients treated at Liverpool Ocular Oncology 124 
Centre. 125 
Variable Value (% or range) 
Age at PM (years) 
Median 64 (16 – 87) 
Gender 
Female 54 (47%) 
Male 63 (53%) 
Survival 
Alive 62 (53%) 
Death from MUM 40 (34%) 
Death other causes 11 (10%) 
Lost to follow-up 4 (3%) 
Median (months) 65 (0 – 132) 
Largest basal diameter (mm) 
Median 15.0 (4 – 22) 
Ultrasound height (mm) 
Median 7.5 (1 – 15.7) 
Ciliary body involvement 
Yes 36 (31%) 
No 81 (69%) 
Extra-ocular extension 
Yes 9 (8%) 
No 108 (92%) 
Epithelioid cells 
Yes 50 (43%) 
No 67 (57%) 
Closed loops present 
Yes 47 (40%) 
No 43 (37%) 
Not assessed 27 (23%) 
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Necrosis 
Yes 21 (17%) 
No 68 (59%) 
Not assessed 28 (24%) 
Mitotic count per 40 high power field 
Median 5 (1–72) 
Primary Management 
Enucleation 78/117 (66%) 
Local Resection 12/117 (10%) 
Endoresection 1/117 (1%) 
Proton Beam RXT 10/117 (9%) 
Ruthenium Plaque RXT 16/117 (14%) 
 126 
Figure 1. Flowchart of 117 UM specimens examined in the present study: n = 76 Frozen-resection (2 127 
post-irradiation); n = 27 Biopsy (24 post-irradiation); n = 14 FFPE. Four patients were lost to follow-up 128 
and excluded from survival analysis. n = 55 were D3, and n = 59 were M3 or ID3. Proportion of cases 129 
with the genetic alteration listed are highlighted by the coloured boxes. Each box represents 5% of 130 
UM patients examined. 131 
2.2. Panel Comparison (14 samples) 132 
Of the initial 14 UM-samples analysed for panel comparison, 1/14 (7%) and 3/14 (21%) failed to 133 
produce reportable SCNA data with the SureSelect (SureSelect XT HS using SureDesign, Agilent) and 134 
TSCA (TruSeq Custom Amplicon using DesignStudio Illumina) panels, respectively. 13/14 (93%) 135 
UM-samples had available SCNA data from previous MLPA for chr1, 3, 6 and 8; the remaining 136 
sample was tested by MSA for chr3 status only. There was 100% agreement for chr3 status between 137 
the MLPA/MSA data and that provided by both NGS tests in this initial sample cohort 138 
(Supplementary Table 1 – samples marked by an asterisk). There was 100% concordance for GNAQ, 139 
GNA11, BAP1, SF3B1 and EIF1AX mutations between both testing platforms. No false positives were 140 
detected in any of the samples. Of note, 6/14 UM test samples had been previously submitted by our 141 
group to the TCGA-UM study, and there was also 100% concordance for all mutations identified. The 142 
SureSelect panel was chosen to test the larger UM cohort, due to its greater success rate in SCNA 143 
analysis and better coverage (Supplementary Table 2).   144 
2.3. Mutation Frequency 145 
In total, 117 UM-samples (including the 14 initial samples analysed) were sequenced using the 146 
above bespoke SureSelect NGS panel. This included 26 UM that had previously undergone PBR or 147 
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PRXT and for which mutation data was successfully obtained. Initiating mutations occurred in 62/117 148 
(53%) for GNAQ; 42/117 (36%) for GNA11; 2/117 (2%) for CYSLTR2 and 1/117 (1%) for PLCB4, which 149 
was concomitant with a GNAQ mutation (Supplementary Table 3). Driver mutations occurred in 150 
50/117 (43%) for BAP1 (1/50 (2%) occurring in a D3-UM); 25/117 (21%) for SF3B1 (3/25 (12%) coincided 151 
with a BAP1 mutation 2/25 (8%) coincided with an EIF1AX mutation, 5/25 (20%) had partial loss or 152 
M3); 22/117 (19%) for EIF1AX (2/22 (9%) occurring in a M3-UM). Interestingly, two D3-UM were 153 
found to have concurrent EIF1AX and SF3B1 mutations.  154 
Novel mutations were observed in: PLCB4: 1/117 p.Met549_Gly556delinsIle; KTN1: 2/117 155 
p.Pro195Thr p.Gln86dup; TTC28: 4/117p. Arg21*, p.Pro1216His, p.Ala18Gly and p.lleI1296Val; 156 
CCMD1: 2/117 p.Pro1097His, p.Pro108Leu; TP53BP1: 2/117 p.Ile455_Pro456del and p.Glu1529*. These 157 
rare variants were confirmed using Integrative Genomics Viewer with a minimum allele frequency 158 
of 30%. No mutations were detected in any of the cases for the genes BRAF, DLK2, FBXW7 or SRSF2.  159 
2.4. SCNA analysis and comparison with MLPA/MSA 160 
We compared the SCNA datasets to establish whether the SureSelect NGS panel accurately 161 
detected SCNA in chr1, 3, 6 and 8 when analysed by MLPA and for chr3 when analysed by MSA. 162 
One sample failed to provide clear SCNA data by NGS and was excluded from the concordance data 163 
below, as were SCNA deemed ‘unclassifiable’ by MLPA. Concordance was observed with NGS as 164 
follows: chr1p - 81/98 (83%); chr3 - 103/112 (92%); chr6p - 68/88 (77%); chr6q - 77/99 (78%); chr8p - 165 
64/102 (63%); and chr8q - 72/97 (74%) (Supplementary Table 1).  166 
SCNA data from the NGS panel was successfully obtained from both non-irradiated and 167 
irradiated samples and demonstrated: loss of 1p in 25/116 (22%) with 8/25 (32%) coinciding with a 168 
concomitant gain of 1q; gains in 1q in 9/116 (8%); M3 in 55/116 (47%); isodisomy 3 (ID3) in 2/116 (2%); 169 
loss of 3p in 1/116 (1%) and loss of 3q in 1/116 (1%), subsequently categorised as partial loss of chr3 170 
(PL3); 6p gain in 46/116 (40%) cases with 37/46 (80%) occurring with D3 and 9/46 (20%) occurring 171 
with M3/ ID3/PL3; 6q loss in 25/116 (22%) of samples with 12/25(48%) occurring with M3/isodisomy 172 
3/PL3;  8p loss in 20/116 (17%) each with a concomitant gain of 8q (Supplementary Table 3). A 173 
complete gain of chr8 was seen in 36/116 (31%) UM. Gain of chr8q only occurred in 75/116 (65%) 174 
samples; 24/75 (32%) in D3 UM and 51/75 (68%) in M3/ID3/PL3 UM. 8q gain varied with respect to 175 
number of extra copies: the median was 2 extra copies for both M3/ID3/PL3 and D3 UM ranging from 176 
1 - 9 in the former group and from 1 – 4 in D3 UM.  177 
2.5. Cox Regression 178 
Univariate analysis was carried out using a significance level of p < 0.005 after Bonferroni 179 
correction. 180 
Factors significantly associated with survival were: epithelioid cytomorphology, LBD, UH, 181 
ciliary body involvement, BAP1 and chr3 status (Table 2). These variables were entered into the Cox 182 
model and backward selection of covariates was carried out using the likelihood ratio to determine 183 
‘goodness of fit’ of the model. At the 0.01 significance level, chr3 loss was significantly associated 184 
with reduced survival (p≤0.001) with a hazard ratio of 5.949 (Table 3).  185 
Table 2. Univariate analysis of n=117 UM patients treated at Liverpool Ocular Oncology Centre. 186 
Variable Sig. Hazard ratio (HR) 
95.0% CI for HR 
Lower Upper 
Age at PM 0.605 1.006 0.983 1.031 
LBD ≤0.001 1.229 1.107 1.365 
UH ≤0.001 1.198 1.086 1.322 
CBI 0.003 2.602 1.396 4.849 
EOE 0.183 2.024 0.717 5.715 
Epithelioid 0.001 4.552 1.910 10.850 
Chr 3 ≤0.001 9.236 3.602 23.683 
Extra copies 8  0.018 2.519 1.174 5.406 
SF3B1 0.131 0.486 0.190 1.241 
BAP1 ≤0.001 6.536 3.095 13.804 
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EIF1AX 0.029 0.269 0.830 0.875 
Table 3. Multivariate analysis of n=117 UM patients treated at Liverpool Ocular Oncology Centre. 187 
Variable Sig. Hazard ratio (HR) 
95.0% CI for HR 
Lower Upper 
UH 0.016 1.124 1.022 1.235 
Chr3 ≤0.001 5.949 2.226 15.898 
Epithelioid 0.059 2.375 0.969 5.825 
2.6. Survival 188 
Kaplan‐Meier survival curves and tables were examined for all primary UM stratified according 189 
to: chr3 status, extra copies of chr8q, and mutations in BAP1 and SF3B1. The following were 190 
significantly associated with a reduced survival time: loss of chr3 (Log Rank p < 0.001), BAP1 191 
mutations (Log Rank p < 0.001), M3-UM with more than two copies of 8q (Log Rank p = 0.014) and 192 
D3-UM with SF3B1 mutations (Log Rank p = 0.027) (Figure 2).  193 
 194 
 195 
Figure 2. Kaplan–Meier survival curves estimate survival in UM patients stratified by: (A) SF3B1 196 
wild-type/mutation status in D3-UM n = 51 (Log Rank, p = 0.027); (B) BAP1 wild-type/mutation status 197 
n = 113 (Log Rank, p < 0.001); (C) Extra copies of chr 8q in M3/ID3-UM n = 59 (Log Rank, p = 0.014) and 198 
(D) SF3B1 wild-type/mutation status in D3-UM n = 51 and Extra copies of chr 8q in M3/ID3-UM n = 199 
59 (Log Rank, p < 0.001). Number of events indicates the number of deaths due to metastatic 200 
melanoma. Log Rank tests were used to compare survival across groups. 201 
2.7. BAP1 IHC 202 
Seventy of the ninety surgical UM-samples (enucleation/local resection) had previously 203 
undergone routine immunohistochemistry (IHC) to determine nuclear BAP1 (nBAP1) protein 204 
expression; the remaining samples did not have enough material for subsequent IHC analysis. nBAP1 205 
protein was absent in 38/70 cases (54%) of which 31 (82%) UM also had mutations in the BAP1 gene. 206 
Of the 7/38 (18%) UM with no BAP1 mutations, four patients had M3-UM and three had died from 207 
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metastatic disease. 3/32 (9%) UM positively expressed nBAP1 protein but had clear mutations in 208 
BAP1, all of which were missense alterations (q.Glu31Lys, q.Cys91Gly and q.Ala142Pro).  209 
2.8. SF3B1 mutations in M3 UM 210 
SF3B1 mutations have previously been associated with D3-UM with late onset metastasis [22]. 211 
In our cohort, 5/25 cases (20%) with SF3B1 mutations had died of metastatic UM at the time of study 212 
closure. Of these five cases, four tumors were D3-UM and one was a M3-UM with a BAP1 mutation. 213 
To investigate the prevalence of SF3B1 mutations in M3-UM that lacked mutations in BAP1, we 214 
identified 20 additional cases of M3-UM where DNA was available and previous IHC analysis had 215 
demonstrated strong nBAP1 positivity, correlating with wild-type BAP1 [28]. This additional UM 216 
cohort consisted of 12 males and 8 females with a mean age of 62 years at primary management 217 
(median age 62; range 45 – 80 years). The mean follow-up period was 48 months (median 61 months; 218 
range 6 – 79 months). Primary management was enucleation 17/20 (85%) and local resection 3/20 219 
(15%). The mean LBD was 14.8 mm (median LBD 14.7; range 9.8 – 22.7mm) with a mean UH of 8.0 220 
mm (median UH 8.4; range 1.7 – 12.4 mm). Full histological assessment is detailed in Supplementary 221 
Table 4. Of these additional 20 UM, 5 (25%) had mutations in SF3B1; 3/5 (60%) q.Arg625Cys and 2/5 222 
(40%) q.Arg625His. At study closure, all five patients were alive; of interest, one patient developed 223 
liver metastases 40 months after primary management but underwent metastasectomy, and is still 224 
alive 25 months after surgery. 225 
3. Discussion 226 
This is the largest study to date to profile UM using bespoke targeted NGS panels. It identified 227 
chr3 as the most significant factor associated with metastatic death and demonstrated for the first 228 
time that irradiated UM-samples can be successfully profiled using NGS with no observable 229 
differences in quality when compared to non-irradiated UM-samples. We identified a subset of M3-230 
UM-patients without nBAP1 loss that demonstrate mutations in SF3B1, and also describe concurrent 231 
disruptive frameshift deletions in SF3B1 and EIF1AX. This is consistent with the observation in one 232 
case sequenced in TCGA that harbored both an EIF1AX and an atypical SF3B1 (T663P) mutation [11]. 233 
We also observed co-occurring mutations in BAP1 and SF3B1 and EIF1AX and SF3B1. Novel 234 
mutations were also identified in TTC28, KTN1, CSMD1 and TP53BP1. Of interest, we identify a 235 
mutation in PLCB4 that does not fall within the hotspot on exon 20 and coincides with a GNAQ 236 
mutation. Furthermore, chr3 results obtained using the NGS panel were comparable to previous 237 
MLPA and MSA analyses. We recommend that this bespoke NGS panel ultimately replaces 238 
MLPA/MSA testing in routine labs, with the possibility of incorporating molecular data into 239 
prognostic tools – e.g. the LUMPO (Liverpool Uveal Melanoma Prognosticator Online) 240 
(https://mpcetoolsforhealth.liverpool.ac.uk/matsoap/LUMPO3CR.htm), which was recently externally 241 
validated in a multicentre study [29]. 242 
3.1. Enrichment comparison 243 
Hybrid capture and PCR-based enrichment methods in NGS vary in how targeted regions are 244 
enriched [30]. Hybrid capture methodologies like the SureSelect XT HS used in this study, involve 245 
shearing gDNA into smaller fragments, library preparation and hybridisation with targeted 246 
biotinylated RNA baits. Using magnetic streptavidin beads these baits can be separated and the 247 
hybridised library amplified; whilst PCR-based methods hybridise a custom oligo pool flanking 248 
targeted regions on unfragmented gDNA. These are then extended and ligated, and PCR is 249 
performed to integrate indexes and sequencing primers. The PCR-based method has the advantages 250 
of requiring lower DNA inputs with shorter preparation times. In our study, hybrid capture 251 
outperformed the PCR-based enrichment in terms of a larger percentage of reads mapped and a 252 
greater mean depth of coverage. Although there were no differences in the ability to call single 253 
nucleotide variants (SNV), there was an increased SCNA analysis failure rate for the PCR-based 254 
method. Similar comparison investigations in other cancer types found limited sensitivity of PCR-255 
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based sequencing, with several variants being missed due to regions of high guanine-cytosine content 256 
and suboptimal PCR conditions, yielding a minimal coverage not found when using hybrid capture 257 
[31-33]. An increased incidence of false positives and missed variants in PCR-based enrichment was 258 
also reported when evaluating hybrid capture versus PCR-based methods for whole-exome 259 
sequencing [34]. In contrast to our comparison, neither study found differences between the success 260 
rates of SCNA analysis.  261 
3.2. Comparison with previous MLPA 262 
In the current study, we were able to successfully examine both SCNA and SNV using a single 263 
NGS assay in fresh, FFPE and also irradiated tissues. Only one sample failed to produce a clear 264 
genotype but this was expected because of a low yield of library post-capture. 10/116 (9%) UM-265 
samples were discordant with the original MLPA/MSA analyses for chr3: 2 were isodisomy 3, which 266 
had been classified as D3 by MLPA due to its limitations in detecting acquired homozygosity; 2 were 267 
shown to have regions of deletion not identified in previous MLPA, most likely due to an increased 268 
number of probes covering chr3 on the NGS panel. Of the remaining six discordant samples, four 269 
had been classified as M3 by MLPA but as D3 by NGS; two of these cases had SF3B1 mutations but 270 
all patients were alive at the study closure. Two had been classified as D3 by MLPA but M3 by NGS; 271 
one had a BAP1 mutation and both patients had died from metastatic disease. For chr1, 6 and 8, the 272 
discordance between the MLPA and the NGS SCNA was greater at 17–26% of UM cases, which is 273 
likely a result of low probe coverage for these chromosomes on the MLPA panel. Whilst the median 274 
8q copy number was the same in D3-UM and M3-UM, the 8q copy number burden was generally 275 
higher in M3-UM. This was reflected by a reduced survival in M3-UM with an 8q copy number of 4 276 
or more consistent with previous reports that 8q dosage is an important predictor of outcome in UM 277 
[11,35].  278 
3.3. Irradiated samples 279 
This is the first study to examine irradiated UM-samples using a NGS panel. No diminished 280 
quality or ability to genotype these tumors was observed amongst these samples. This is consistent 281 
with our findings using MSA/MLPA to genotype irradiated UM [36-38].   282 
3.4. BAP1 mutations 283 
The frequency of BAP1 mutations in the present study was 43% in total, occurring in 82% of M3-284 
UM; these data are consistent with the findings of others [11,14,19,25]. The presence of a BAP1 285 
mutation in UM was associated with a worse survival. We have previously reported that nBAP1+ M3-286 
UM have a better prognosis as compared with nBAP1- M3-UM [21]; however, interestingly in this 287 
current study, M3-UM that were wild-type for BAP1 (10/57; 18%) did not correlate with an increased 288 
survival time as compared with M3-UM with BAP1 mutations. This may be due to either the 289 
observation that BAP1 mutations do not always correlate with loss of nBAP1 protein expression, or 290 
to the smaller cohort of patients in the present study [28,39].  291 
3.5. SF3B1 mutations 292 
The frequency of SF3B1 mutations in UM ranges in the literature from 11%-34% [14,25], and in 293 
this study SF3B1 mutations occurred in 21% of cases. SF3B1 mutations are reported to occur mainly 294 
in D3-UM associated with late onset metastasis and decreased survival (22). This is consistent with 295 
our study in which 20/25 (80%) SF3B1 mutations occurred in D3-UM with a significantly reduced 296 
survival time as compared with D3/SF3B1wt UM (p=0.027). A novel disruptive frameshift deletion in 297 
SF3B1 of 15 nucleotides was observed in p.Lys653_Ser657del on heat domain 4, outside the hotspot 298 
region of codon 625; the significance of this is unclear. Of particular interest in our study are five M3-299 
UM or UM with PL of chromosome 3 with SF3B1 mutations. Two of these UM harboured BAP1 300 
mutations, previously described in one other study (11); one patient succumbed to metastatic disease 301 
12 months after primary management, and the second patient died of other causes 99 months (8.25 302 
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years) later. Three SF3B1 mutations were recorded in M3-BAP1wt UM, a phenomenon only observed 303 
in one other study to date [11]. To examine this further, we tested an additional 20 cases of M3-UM 304 
with nBAP1 positivity, and identified five cases with SF3B1 mutations; at the time of study closure, 305 
all five patients were alive. Additional cases and longer follow-up are required to fully understand 306 
the clinical relevance of SF3B1 mutations in M3-UM. 307 
3.6. EIF1AX mutations 308 
EIF1AX mutations were detected in the present study in 19% of UM, which is consistent with 309 
that reported by other groups [11,14,18,25]. Interestingly, two UM demonstrated mutations in both 310 
EIF1AX and SF3B1 despite previous reports describing that these occur in a mutually exclusive 311 
manner [11,25]. Of note, both patients died from metastatic disease at 34 and 58 months, respectively, 312 
after primary treatment. EIF1AX mutations are typically associated with D3-UM; however, we 313 
identified two M3-UM that displayed mutations in this gene. A novel disruptive frameshift deletion 314 
of 6 nucleotides from the coding sequence was also identified in p.Arg14_Gly15del of EIF1AX.  315 
3.7. Initiating Mutations 316 
Mutations in GNAQ and GNA11 occurred in 89% of UM in a mutually exclusive manner (53% 317 
and 39%, respectively), consistent with the literature [11,14,25]. Mutations predominantly occurred 318 
in exon 5 for GNAQ and GNA11, and two UM had mutations in exon 4. One sample contained two 319 
unusual mutations in exon 4 of GNA11 p.R214K and p.R214S. These regions do not lie within any of 320 
the known functional domains of GNA11 and have not been previously described; their effect on 321 
GNA11 protein function is unknown. Mutations in CYSLTR2 were found in two UM in the hot spot 322 
region p.L129Q in exon 1 and occurred in a mutually exclusive manner to mutations in GNAQ and 323 
GNA11, as previously reported [17]. Consistent with our general understanding of the function of 324 
these mutations, there were no differences in survival outcome based on the mutational status of the 325 
driver mutations GNAQ, GNA11 and CYSLTR2.  326 
Disruptive frameshift deletions in p.M549_G556delinsI and M561_G568delinsI mutations were 327 
observed in PLCB4 in a single UM sample. This cases also showed a p.R183Q mutation in GNAQ. 328 
Previous studies identified recurrent mutations in PLCB4 in a hot-spot region p.D630Y and p.D630N 329 
on exon 20 [18]. The mutation identified in our study occurred in exon 18 and is the first mutation in 330 
this region to be described in UM. Though it was initially thought that PLCB4 mutations occurred in 331 
a mutually exclusive manner to GNAQ, GNA11 and CYSLTR2, our study and that of Robertson et al. 332 
[11] demonstrate PLCB4 mutations concurrent to GNAQ and GNA11 mutations.   333 
3.8. Other Mutations 334 
We observed low frequency (3%) somatic mutations in genes originally identified by Royer-335 
Bertrand et al. (6%), namely in TTC28, CSMD1, KTN1 and TP53BP1 [14]. Most of these genes are 336 
involved in various cellular processes, e.g. cell cycle regulation [40], cell migration and proliferation 337 
[41,42], kinesin binding [43] and DNA double-strand break repair [44]. Our NGS panel was custom-338 
designed to have full coverage of the TTC28, CSMD1, KTN1 and TP53BP1 genes, and because of its 339 
targeted nature had greater coverage in comparison to whole-exome sequencing methodologies. Due 340 
to their low frequency in this study, no association could be made between the mutations in TTC28, 341 
CSMD1, KTN1 or TP53BP1, and UM with particular clinical or morphological features. It is worth 342 
noting that previously described mutations in SRSF2, DLK2 or FBXW7 were not detected in this large 343 
study [14,20,45]. 344 
4. Materials and Methods: 345 
4.1. Patients 346 
In this retrospective cohort study, primary UM-samples were collected from 117 patients who 347 
were treated at the Liverpool Ocular Oncology Centre (LOOC), Royal Liverpool University Hospital 348 
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NHS Trust, between January 2008 and May 2015. This time period was chosen to allow sufficient 349 
follow-up (median, 65 months). The follow-up period was calculated from date of primary 350 
management to either study end (23/09/2019) or to death from metastatic disease or other causes. 351 
Patients were treated either by radiotherapy or surgical resection, and their UM was genotyped using 352 
either MLPA or MSA, as described below.  353 
4.2. Specimen characteristics 354 
Specimens consisted of DNA (stored at -80°C) previously extracted from fresh biopsies all 355 
preserved in CytoLyt (Cytyc Corp) and stored at 4°C, fresh- tumor tissue all snap-frozen in liquid 356 
nitrogen and stored at -80°C, and FFPE UM-samples stored at room temperature. Twenty-six of the 357 
DNA samples analysed were post-irradiation specimens. 358 
4.3. Study Design 359 
The clinical endpoint examined in this study was death from metastatic disease. Patients who 360 
died from causes other than those relating to UM were included in the study, and data for these 361 
records were treated as right-censored cases for evaluation purposes. This study conformed to the 362 
principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Approval for the 363 
study was obtained from the Health Research Authority South Central - Hampshire B Research Ethics 364 
Committee (REC ref 15/SC/0611). All samples and data were provided by the Ocular Oncology 365 
Biobank (REC ref 16/NW/0380). All patients had provided informed consent for the use of their 366 
samples and data in research. 367 
4.3. Assay Methods: 368 
4.3.1. Morphological/Histological Studies 369 
All samples underwent routine histopathological and cytological workup assessing cell type, 370 
mitotic count, and presence of PAS+ connective tissue loops where possible (28). 90/117 enucleation 371 
and local resection specimens had a full histological workup, whilst 27/117 biopsies and 372 
endoresection specimens underwent cytological examination only. Additionally, IHC analysis of 373 
nBAP1 expression was undertaken in 70/117 cases, as described previously [21].  374 
4.3.2. DNA extraction and quantification 375 
Methods for DNA extraction from FFPE and frozen UM have been published elsewhere [46]. DNA 376 
integrity of FFPE samples was qualified by performing a qPCR using the Agilent NGS FFPE QC Kit.  377 
4.3.3. Chromosomal SCNA Analysis 378 
MLPA (MRC Holland, The Netherlands) and MSA were used to assess SCNA, and subsequent 379 
comparison with NGS data were undertaken during routine genetic testing of patient samples, as 380 
previously described [47,48]. Cases yielding >100 ng of DNA were tested using MLPA, whilst MSA 381 
was undertaken for UM-samples with lower DNA yields.  382 
4.3.4. Next-Generation Sequencing  383 
Two custom NGS panels were designed: SureSelect XT HS using SureDesign (Agilent) and 384 
TruSeq Custom Amplicon (TSCA) using DesignStudio (Illumina). Both panels were designed to 385 
cover mutations in GNAQ (exons 4 & 5), GNA11 (exons 4 & 5), SF3B1 (exons 12 & 14), EIF1AX (exons 386 
1 & 2), and all exons of BAP1, FBXW7, DLK2, CSMD1, CYSLTR2, KTN1, TP53BP1, SRSF2, PLCB4, 387 
TTC28 and BRAF (negative control). Both enrichment methods included incorporation of unique 388 
molecular identifiers or barcodes to reduce errors and quantitative bias introduced by the 389 
amplification process. For the SureSelect XT HS additional probes were included to examine SCNA 390 
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in chr1: 1541 probes; chr3: 1287 probes; chr6: 1094 probes; chr8: 933. The TSCA panel included 391 
additional probes to examine SCNA in chr3: 83 amplicons; chr6: 76 amplicons and chr8: 67 amplicons. 392 
Chr1 was not included in the TSCA NGS panel due to tiling limitations. As the panels were worked 393 
up on larger resection samples, the DNA input was 50ng for both panels. Libraries were constructed 394 
using either the SureSelect XT HS Reagent + Capture Library Kit (Agilent) or TruSeq Custom 395 
Amplicon Low Input Kit (Illumina), according to manufacturer’s instructions. The two panels were 396 
tested and compared using 14 frozen UM-samples, 8 of which had been previously profiled by The 397 
Cancer Genome Atlas (TCGA) UM study [11] and 6 had available data from previous genotyping 398 
plus an additional two reference samples (Genome In A Bottle, HDx).  399 
The SureSelect XT HS was subsequently selected to test a larger cohort of 95 fresh and 13 FFPE 400 
UM-samples with reference samples included in each sequencing run. The DNA input varied (5ng-401 
25ng) depending upon the sample type. 402 
4.3.5. Sanger Sequencing 403 
Exon 14 of SF3B1 was sequenced using PCR-based capillary Sanger sequencing in an additional 404 
twenty M3-UM with unusual nBAP1+ protein expression [21]. Oligonucleotides were constructed by 405 
Eurofins Genomics; forward 5’-GGCCGAGAGATCATTTCT-3, reverse 5’-406 
AAGAAGGGCAATAAAGAAGGA-3’, product size 289bp. PCR was performed in a reaction volume 407 
of 50μl containing 100ng of genomic DNA, 0.25μl of Thermo-Start Taq DNA Polymerase (Thermo 408 
Scientific), 5μl of HP Buffer, 4μl 25 mM MgCl2, 2μl of dNTP (2mM each), 31.25μl Nuclease Free water 409 
and 1μl of each of the primers. The thermal cycling profile was as follows: initial denaturation at 95 410 
°C for 15min and 35 rounds of amplification at 95°C for 15s, 55℃ for 30s and 72°C for 1min. A final 411 
extension step at 72°C for 5 min was added. PCR products were purified using the QIAquick PCR 412 
purification kit (Qiagen) according to the manufacturer's protocol. Sequencing of PCR products was 413 
carried out by GATC at Eurofins Genomics in accordance with ISO 17025. Sequencing data were 414 
analysed using Chromas Lite (2.1.1., Technelysium Pty Ltd).  415 
4.4. NGS Data Analysis 416 
NGS libraries were sequenced on the Illumina MiSeq platform (2x 250 bp paired-end) by the 417 
Centre for Genomic Research (www.cgr.liv.ac.uk), University of Liverpool, UK. Base-calling and de-418 
multiplexing of indexed reads were performed by CASAVA version 1.8.2 (Illumina) to produce the 419 
raw sequence data in FASTQ format. The raw FASTQ reads were trimmed to remove Illumina 420 
adapter sequences using Cutadapt version 1.2, and low-quality bases using Sickle version 1.200. 421 
Trimmed reads were aligned to the human GRCh37 reference genome (ftp://ftp-422 
trace.ncbi.nih.gov/1000genomes/ftp/technical/reference/phase2_reference_assembly_sequence/hs37423 
d5.fa.gz) with the short-read alignment tool, BWA-MEM (version 0.7.5a-r405). Following alignment, 424 
PCR and optical duplicate reads were identified and removed with UMI-tools 425 
(https://github.com/CGATOxford/UMI-tools). Subsequently, the Genome Analysis Toolkit (GATK) 426 
(version 3.7) Indel Re-aligner module was used to locally realign reads around the putative insertion 427 
and deletion sites. GATK BaseRecalibrator module was used for recalibrating the base calls. The 428 
aligned data were then analysed using tCoNut (https://github.com/tgen/tCoNuT) to detect SCNAs. 429 
The variants were called by GATK and annotated by SNPeff.  430 
4.5. Statistical Analysis Methods 431 
Survival time (months) was calculated from the date of primary management until death from 432 
metastases or study closure on 23/09/2019. Median survival time was estimated using the Kaplan-433 
Meier product limit method. Univariate associations between survival time, clinical, histological and 434 
genetic features were examined using Cox proportional hazards regression models. Analyses were 435 
undertaken using SPSS Statistics v.24 (IBM), Microsoft R 3.5.1 and the packages rms, cmprsk and 436 
mstate. Cut-offs for SCNA used established values based on previous clustering analysis carried out 437 
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at our centre: log rank < 0.85 loss, > 1.15 amplification [49]. The allelic frequency threshold to call a 438 
mutation was 10%. 439 
5. Conclusion 440 
Our bespoke UM NGS panel enables detailed CNV and mutational information to be obtained 441 
from small UM biopsies, FFPE material and previously irradiated UM.  This is in distinct contrast to 442 
some current methodologies, which when applied to biopsies can only determine chr3 status due to 443 
the low DNA yield. Moreover, consistent with other reports, BAP1 and SF3B1 mutations in addition 444 
to 8q copy number are of added importance when determining patient outcome, and moves UM 445 
stratification away from a binary genetic classification based on chr3 copy number only.  Identifying 446 
metastatic risk groups with greater precision than is currently possible with SCNA assessment alone 447 
will have implications on the frequency at which patients are followed up for subsequent liver 448 
imaging, and the imaging techniques applied, as well as on patient selection for clinical trials. 449 
Although at present mutations in UM are not therapeutically actionable, it is hoped that continued 450 
advances in our understanding of this disease will result in the use of these biomarkers to predict 451 
response to emerging therapies.  452 
  453 
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